Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

479 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study.
Hillert J, Butzkueven H, Magyari M, Wergeland S, Moore N, Soilu-Hänninen M, Ziemssen T, Kuhle J, Pontieri L, Forsberg L, Aarseth JH, Zhu C, Sicignano N, Mushnikov V, Bezemer I, Sabidó M. Hillert J, et al. Among authors: ziemssen t. Clin Epidemiol. 2024 Oct 17;16:717-732. doi: 10.2147/CLEP.S480525. eCollection 2024. Clin Epidemiol. 2024. PMID: 39435029 Free PMC article.
The CLARION study: first report on safety findings in patients newly initiating treatment with cladribine tablets or fingolimod for multiple sclerosis.
Butzkueven H, Hillert J, Soilu-Hänninen M, Ziemssen T, Kuhle J, Wergeland S, Magyari M, Berger JR, Moore N, Aydemir A, Bezemer I, Sabidó M. Butzkueven H, et al. Among authors: ziemssen t. Curr Med Res Opin. 2023 Oct;39(10):1367-1374. doi: 10.1080/03007995.2023.2256220. Epub 2023 Sep 7. Curr Med Res Opin. 2023. PMID: 37675878
Multiple sclerosis registries in Europe - An updated mapping survey.
Glaser A, Stahmann A, Meissner T, Flachenecker P, Horáková D, Zaratin P, Brichetto G, Pugliatti M, Rienhoff O, Vukusic S, de Giacomoni AC, Battaglia MA, Brola W, Butzkueven H, Casey R, Drulovic J, Eichstädt K, Hellwig K, Iaffaldano P, Ioannidou E, Kuhle J, Lycke K, Magyari M, Malbaša T, Middleton R, Myhr KM, Notas K, Orologas A, Otero-Romero S, Pekmezovic T, Sastre-Garriga J, Seeldrayers P, Soilu-Hänninen M, Stawiarz L, Trojano M, Ziemssen T, Hillert J, Thalheim C. Glaser A, et al. Among authors: ziemssen t. Mult Scler Relat Disord. 2019 Jan;27:171-178. doi: 10.1016/j.msard.2018.09.032. Epub 2018 Oct 4. Mult Scler Relat Disord. 2019. PMID: 30384204 No abstract available.
Escalating to medium- versus high-efficacy disease modifying therapy after low-efficacy treatment in relapsing remitting multiple sclerosis.
Müller J, Roos I, Kalincik T, Lorscheider J, Galli E, Benkert P, Schädelin S, Sharmin S, Einsiedler M, Hänni P, Schmid J, Kuhle J, Derfuss T, Granziera C, Ziemssen T, Siepmann T, Yaldizli Ö. Müller J, et al. Among authors: ziemssen t. Brain Behav. 2024 May;14(5):e3498. doi: 10.1002/brb3.3498. Brain Behav. 2024. PMID: 38688877 Free PMC article.
Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis.
Callegari I, Schneider M, Aebischer V, Voortman MM, Proschmann U, Ziemssen T, Lindberg R, Fischer-Barnicol B, Khalil M, Kappos L, Kuhle J, Sanderson NSR, Derfuss T. Callegari I, et al. Among authors: ziemssen t. Ther Adv Neurol Disord. 2023 Jan 30;16:17562864221150040. doi: 10.1177/17562864221150040. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 36741352 Free PMC article.
479 results